MFR of a GMP lot of lentiviral vector encoding a CD19/CD22 targeting bispecific chimeric antigen receptor (CD19/CD22 bicar) gene for clinical use

Ended Purchase Order Awarded Last action

Contract number
HHSN261201600014A
Awardee
Awarding agency
Obligated
$322,000

Award facts

Opportunity
Contract value 100% obligated
$322,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325413 In-Vitro Diagnostic Substance Manufacturing
PSC
Q301 Reference Laboratory Testing
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Gaithersburg, MD 20878, USA

Award details come from SAM.gov/FPDS.

About this award

This is a firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lentigen Technology, Inc. for the manufacture of a good manufacturing practice (GMP) lot of a lentiviral vector encoding a CD19/CD22 targeting bispecific chimeric antigen receptor (CD19/CD22 BiCAR) gene for clinical use. The contract has a ceiling value of $322,000.00 and a completion date of August 7, 2017. The contract was awarded on August 8, 2016 and was not set aside for any specific business type.

Quick answers

Who was awarded contract HHSN261201600014A?

HHSN261201600014A was awarded to Lentigen Technology, Inc. by National Cancer Institute (National Institutes of Health) on August 8, 2016.

How much is contract HHSN261201600014A worth?

The government has obligated $322,000 on HHSN261201600014A.

Was contract HHSN261201600014A competed?

The extent of competition for HHSN261201600014A was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award